July 13, 2022
The health ministry on July 12 presented the number of defects and health damages reported for regenerative medicine products in a six-month period through March 2022, with Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) logging the highest figure in Japan at...read more